Presented by: Anna Podolanczuk, MD, MS & Sandeep Bansal, MD, FCCP, FACP
In this webinar, speakers will discuss updated IPF/PPF guidelines, key utility data, and the role of the Envisia Genomic Classifier in the diagnosis and prognosis of ILD. New data will be presented that demonstrates how the Envisia Classifier can predict clinical progression in fibrotic ILD.
POSTER #4812 | CHEST 2022
Positive Envisia Genomic Classifier Result Predicts Clinical Progression in Fibrotic Interstitial Lung Disease
Presented by: Lisa Lancaster, MD, FCCP
Poster #2019 |CHEST 2022
Demonstrating Clinical Utility for a Nasal Swab Genomic Classifier for Lung Nodules: Addressing the Clinical Trial Learning Curve with a Familiarization Phase
Presented by: Dr Michael Bernstein, MD, FCCP
Start a conversation
Contact us for more information or if you have any questions about Veracyte’s suite of genomic tests for lung disease.